Harwood Feffer LLP Files Class Action Suit Against Jiangbo Pharmaceuticals, Inc.

Harwood Feffer LLP ( www.hfesq.com) announced today that a class action complaint has been filed against Jiangbo Pharmaceuticals, Inc. (“Jiangbo” or the “Company”) (Nasdaq:JGBO -News) and certain of the Company’s officers for violations of the Securities Exchange Act of 1934. The action, brought on behalf of those purchasing the common stock of Jiangbo between June 8, 2010 through May 31, 2011, inclusive (the “Class Period”), is pending in the United States District Court for the Southern District of Florida.

No class has yet been certified in the above action. Class members will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than September 14, 2011 and be selected by the court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages to serve as a lead plaintiff. You may contact Harwood Feffer LLP at its website ( http://www.hfesq.com) or by email to [e-mail] to ask any questions you may have in that regard.

Jiangbo researches and develops pharmaceutical products in China. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup, and electuary form. Accordingly to the Complaint, throughout the Class Period, Defendants made materially false and misleading statements to investors by materially overstating the Company's cash balances and failing to disclose that Jiangbo's internal controls over financial reporting were inadequate.